Zsuzsanna M.

Research emphasis spans Crohn’s Disease, Ulcerative Colitis, and related immune‑mediated intestinal disorders, with focus on induction and maintenance regimens.

• Biologic and small‑molecule agents for moderate‑to‑severe IBD
• Endoscopic response endpoints
• Oral therapies targeting gut inflammation
• Long‑term safety monitoring in chronic IBD

Active enrollment occurs through the department’s dedicated IBD clinic.

Key interests include Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis with Nasal Polyps, and severe asthma phenotypes, integrating biologic modulation of airway inflammation.

• Exacerbation reduction in COPD
• Nasal polyp burden and symptom relief
• Biomarker‑driven asthma therapeutics
• Safety profiling of inhaled and systemic agents

Collaboration with ENT and pulmonology units enhances multidisciplinary trial delivery.

Investigator contributes to studies on Acute Ischemic Stroke and high‑risk Transient Ischemic Attack, as well as neurodegenerative conditions like Parkinson's disease and demyelinating disorders including Primary Progressive Multiple Sclerosis and Secondary Progressive Multiple Sclerosis.

• Antithrombotic strategies post‑stroke
• Neuroprotective agents for Parkinson’s disease
• Immune‑modulating therapies for progressive MS
• Functional outcome assessments in cerebrovascular trials

Neurology services at the host hospital provide the clinical infrastructure for these investigations.

Clinical focus includes Myelodysplastic Syndromes, Primary Myelofibrosis, Post‑Polycythemia Vera/Myelofibrosis, and immune‑mediated cytopenias such as Primary Immune Thrombocytopenia.

• Novel agents for myelofibrosis management
• Targeted therapies for HRR‑mutated hematologic malignancies
• Safety and efficacy of long‑term disease‑modifying treatments
• Transfusion‑independent strategies in MDS

Hematology clinic integration ensures comprehensive patient monitoring throughout trial participation.